APT Medical Inc. — Cyborg Score 7/10

Strong
Medical Devices & Equipment Manufacturing - Cardiovascular Interventional Devices

Strategic Profile

In 2024, APT Medical's revenue was 2.07 billion, an increase of 25.18% compared to the previous year's 1.65 billion. APT Medical Inc. was founded in 2002 and is based in Shenzhen, China. The company is positioned as a leading supplier of specialized medical devices in the Asian market with strong R&D capabilities and OEM/ODM service offerings.

Cyborg Score Rationale

The company demonstrated revenue growth of 25.18% in 2024 with earnings up 26.14%, indicating strong market traction and profitability. APT Medical maintains competitive advantages through specialized product portfolio and long-term market presence, though operating in a competitive medtech sector.

Top Insights

  • Strong double-digit revenue and earnings growth in 2024 signals robust market demand for cardiovascular interventional devices
  • Comprehensive product portfolio spanning electrophysiology, interventional cardiology, peripheral intervention, and neurointervention reduces client dependency
  • OEM/ODM services diversify revenue streams and provide contract manufacturing capabilities across multiple medical device categories
  • Strategic value recognized by Mindray with attempted acquisition, validating market position within China's medical device ecosystem

Named Competitors

  • Electrophysiology & Interventional Devices — Global leader in cardiovascular and electrophysiology devices
  • Electrophysiology & Interventional Devices — Major competitor in cardiac rhythm management and interventional solutions
  • Electrophysiology & Interventional Devices — Leading provider of interventional medical devices
  • Electrophysiology & Interventional Devices — Chinese medical device manufacturer with strategic stake acquisition interest

Recent Developments

  • (August 2025) Successful completion of first pulsed-field atrial fibrillation ablation procedures in Indonesia using APT Medical technology
  • (February 2026) Company continues expansion of pulsed field ablation capabilities with clinical trials underway for advanced mapping and ablation systems
  • (2024) Revenue reached 2.07 billion CNY, up 25.18% year-over-year with improving profitability

Open the full interactive APT Medical Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →